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A B S T R A C T
Purpose: Many studies had demonstrated that MRI T1-weighted imaging was the most accurate method to
evaluate the intramedullary extent of extremity osteosarcoma. However, we found that after neoadjuvant
chemotherapy new low signal of MRI T1 imaging was detected near tumor, which mimicked the tumor
progression. The aim of this study was to describe the incidence and type of this new signal, to reveal the
pathological correlation with this imaging change.
Methods: We included 74 extremity osteosarcomas managed between June 2011 and November 2012 in this
retrospective study. The T1-weighted MRI images of the aﬀected extremity before and after neoadjuvant
chemotherapy were reviewed and compared. The subjects were then classiﬁed according to the appearance of
the border between the area involved by osteosarcoma and the normal marrow with attention paid to whether
the border was continuous and the width of the zone of transition. The study population was classiﬁed into one
of four classiﬁcations: ‘clear’, ‘continuous diﬀuse’, ‘discontinuous island-like’ and ‘discontinuous diﬀuse’. 11
patients underwent MRI of bilateral extremities, and for these patients we assessed the appearance of the
uninvolved extremity with that with osteosarcoma. Following surgical resection of the tumor, the pathologic
appearance was compared with the pre-operative MRI ﬁndings.
Results: According to our classiﬁcation system, all 74 subjects were ‘clear’ before neoadjuvant chemotherapy.
After neoadjuvant chemotherapy, 30 subjects (40.5%) were still clear. Of the 44 subjects (59.5%) not classiﬁed
as ‘clear’, 22 (29.7%) were classiﬁed as ‘continuous diﬀuse’, 4 (5.4%) as ‘discontinuous island-like’, and 18
(24.3%) as ‘discontinuous diﬀuse’. Of the subjects with MRI of bilateral femurs, no radiologic diﬀerence was
noted in the normal marrow bilaterally. No signiﬁcant diﬀerence in overall survival and relapse free survival was
noted between patients grouped according to the subtypes of MRI noted.
Conclusions: Neoadjuvant chemotherapy for extremity osteosarcoma can result in a variety of changes of the
MRI appearance of tumor and adjacent bone and marrow. Areas of signal change beyond the tumor that
represent marrow conversion and not tumor progression appear on T1 weighted imaging to be lower in signal
than subcutaneous fat and higher in signal than muscle. Recognizing the existence of the eﬀect of neoadjuvant
chemotherapy on the MR appearance of the tumor and surrounding bone and myeloid elements is important so
as to plan for oncological sound tumor resections while avoiding resecting more normal bone than necessary.
1. Introduction
Many studies had demonstrated that magnetic resonance imaging
(MRI) T1-weighted imaging is the most accurate method to evaluate
the intramedullary extent of extremity osteosarcoma [1–4]. However,
we have found that after neoadjuvant chemotherapy, an area of low
signal intensity on T1-weighted MRI was detected near tumor, the
radiologic appearance of this suggested tumor progression, but on
subsequent pathologic examination showed no involvement by tumor.
The aim of this study was to describe, and classify the diﬀerent types of
these signal changes and to report their incidence. Correlation of these
imaging ﬁndings with pathological ﬁndings was also performed.
2. Materials and methods
The prospectively collected sarcoma database of the Orthopaedic
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Oncology Department of Beijing Jishuitan Hospital was searched to
identify all patients treated for osteosarcoma.
Of extremities between June 2011 and November 2012. Among
these patients, we included patients with two or more pre-operative
MRI scans available in the electronic picture archiving and commu-
nications system (PACS), including one pre-chemotherapy and one
post-chemotherapy scan. All the patients were biopsied for the
diagnosis of osteosarcoma. Patients with pathological fracture and
who had previously undergone surgery at the site of the tumor were
excluded. Patients with osteosarcoma of the ﬁbula were excluded
because the marrow space was too narrow to evaluate on MRI.
The study group thus consisted of 74 patients [male, 45; female, 29;
median age: 15 years (range, 9–25 years)]. The tumor was located in
distal femur in 39 patients, proximal tibia in 26 patients, proximal
humerus in 7 patients, proximal femur and distal tibia in 1 patient
each.
Neoadjuvant chemotherapy was given following histologic conﬁr-
mation of the diagnosis. The chemotherapy regimen included high-
dose Methotrexate, Ifosfamide Cisplatin and Doxorubicin. The leuko-
penia was found in all patients during chemotherapy and the G-CSF
was given to stimulate the marrow hyperplasia. Staging studies
included plain radiographs, computed tomography (CT) and MRI of
the limb, CT scans of the chest and total body scintigraphy. MRI of the
aﬀected extremity was the most important imaging modality for
evaluation of the local extent of the tumor. All these patients received
limb salvage surgery and the planning of the bony resection level was
done by the operating orthopaedic oncologist and a radiologist.
MRI examinations, performed at our institution, were included in
the study if they contained at least pre-chemo and post-chemo T1-
weighted imaging. The imaging was analyzed on our PACS for this
study. The coronal section was reviewed by one senior surgeon and one
radiologist independently. After neoadjuvant chemotherapy, the signal
change types were recorded. Eleven patients received the bilateral limb
MRI examination and the normal side imaging was compared with the
side aﬀected by osteosarcoma.
Following surgical resection, specimens underwent pathological
examination with the specimen prepared in a coronal section with a
band saw. Areas noted on MRI with speciﬁc imaging characteristics
were correlated with the pathologic ﬁndings in the specimen. A
separate biopsy was performed at the time of surgery in the areas of
intermediate signal intensity area when this area was not within the
resection specimen.
All the patients were followed up according to our protocol, which
included follow up every 3 months for the ﬁrst 2 years, every 4 months
for the third and fourth years, and every 6 months for the ﬁfth year. Their
oncological outcomes were recorded from a review of their case notes.
Fig. 1. ‘Clear’ type with distinct boundary between tumor and the normal marrow.
Fig. 2. ‘Continuous diﬀuse’ type with area of intermediate signal contiguous with the
area of tumor.
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3. Results
3.1. Type of signal
The shape of MRI T1-weighted imaging was classiﬁed into four
groups: ‘clear’, ‘continuous diﬀuse’, ‘discontinuous island-like’ and
‘discontinuous diﬀuse’.
1. Clear: The area with tumor has low signal intensity and normal fatty
marrow has high signal intensity with distinct margin between the
two areas (Fig. 1).
2. Continuous diﬀuse: There is an area with signal intensity higher
than skeletal muscle and lower than fat between the tumor and
normal fatty marrow. This area with intermediate signal was
contiguous with the tumor, and was not patchy in appearance
(Fig. 2).
3. Discontinuous diﬀuse: The area with intermediate signal intensity
was patchy and diﬀuse in appearance, not contiguous with the
tumor, and intermingled with areas with the normal fat signal
(Fig. 3).
4. Discontinuous island-like: The area of intermediate signal was
beyond the tumor and the normal fat signal could be seen between
them. (Fig. 4)
3.2. The incidence of signal change
Before neoadjuvant chemotherapy all 74 cases were ‘clear’. After
neoadjuvant chemotherapy, 30 cases (40.5%) were still classiﬁed as
clear. Signal change from clear to another classiﬁcation occurred in 44
cases (59.5%), including 22 ‘continuous diﬀuse’ (29.7%), 4 ‘discontin-
uous island-like’ (5.4%), 18 ‘discontinuous diﬀuse’ (24.3%).
The post-chemotherapy MRI showed bilateral extremities in 11
cases, with all of these being femurs. The marrow signal in the normal
femur was the same as the normal marrow in the osteosarcoma femur
(Fig. 5). The histological studies showed no tumor cells but the
hematopoietic cells.
3.2.1. Pathological correlation
In no patient was tumor were seen in the area of intermediate signal
intensity. Histologically, only hematopoietic cell proliferation (Fig. 6a
and b) was noted.
3.2.2. Follow-up
The duration of follow-up was 1 month to 57 months. The median
follow up was 37 months. The follow up duration for patients who were
alive at last follow up was from 18 months to 57 months. Only one
patient developed local recurrence and died of metastasis later. Sixteen
patients developed metastasis. At the end of follow-up, Seventeen
patients died of the disease. The overall survival of patient in this study
is shown in the Fig. 7. There was no signiﬁcant diﬀerence between
Fig. 3. ‘Discontinuous diﬀuse’ type with patchy appearance of the area of intermediate
signal.
Fig. 4. ‘Discontinuous island-like’ with an area of intermediate signal not contiguous
with the tumor signal beyond the tumor.
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patients with the four types of MRI ﬁndings in both overall survival and
relapse free survival (Fig. 8 and 9).
4. Discussion
The results of our study show that, after neoadjuvant chemotherapy
of osteosarcoma, signal changes are common at MRI in the marrow of
long bones, including 29.7% ‘continuous diﬀuse’, 5.4% ‘discontinuous
island-like’, 24.3% ‘discontinuous diﬀuse’.
The survival of osteosarcoma patients has increased dramatically
due to the chemotherapy [5,6]. MRI has been widely used to evaluate
the extent of tumor during neoadjuvant chemotherapy of osteosarco-
ma. Because of regenerating red marrow, signal intensity decreases on
T1-weighted images. We can see the new signal in MRI which is
haematopoietic marrow mimicking tumor. These haematopoietic cells
are generally bilateral and symmetric, which is demonstrated in our
study.
Fig. 5. T1 – weighted image of patient with osteosarcoma of the left femur showing
similar changes in the shafts of the femurs bilaterally.
Fig. 6. a: Coronal section of a resection specimen. The site of intermediate signal intensity is marked by the arrow. b: Photomicrograph of specimen in a: showing no tumor cells, and
only hematopoietic cell proliferation.
Fig. 7. Kaplan–Meier survival curve showing overall survival for all patients in the
study.
Fig. 8. Kaplan–Meier survival curve showing overall survival for subjects classiﬁed
according to the four imaging subtypes: Type 1, clear. Type 2, continuous diﬀuse. Type 3,
discontinuous diﬀuse. Type 4, discontinuous island-like.
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Granulocyte colony-stimulating factor (GCSF) is used to stimulate
myeloid cell production in osteosarcoma patients undergoing che-
motherapy. Some studies have described the MRI signal changes noted
in patients after the use of GCSF [7–9]. The signal changes may be
homogeneously diﬀuse, mimicking tumor progress or metastases.
These changes may also be noted symmetrically and bilaterally, or
asymmetrically. Awareness of the occurrence of these changes is
important to avoid an incorrect diagnosis of tumor progression or
metastases. Our study shows how commonly this phenomenon of
marrow reconversion can be noted on MRI when GCSF was adminis-
tered to patients with osteosarcoma. The oncological results show that
there is no signiﬁcant diﬀerence patients with the four subtypes of this
ﬁnding of MRI. The use of GCSF can stimulate the signal change in the
marrow but this change is not related to the oncological results.
In conclusion, we have described the types and incidence of the
signal changes that can be noted after neoadjuvant chemotherapy in
patients with extremity osteosarcoma. These areas intermediate in
signal intensity to subcutaneous fat and normal muscle on T1-weighted
MRI imaging signals represent marrow conversion and not tumor
progression. Recognition of this type of change can avoid resecting
more normal bone in limb salvage surgery.
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Fig. 9. Kaplan-Meier survival curve showing relapse free survival classiﬁed according to
the four imaging subtypes: I. Type 1, clear. Type 2, continuous diﬀuse. Type 3,
discontinuous diﬀuse. Type 4, discontinuous island-like.
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